FDA approves Novartis’ MS drug Kesimpta for treating relapsed forms of the disease
The Pharma Data
AUGUST 21, 2020
Kesimpta targets and delivers B-cell therapy and has shown to have superior efficacy and safety profile compared to similar treatments. The US regulator originally approved the drug in 2009 for the treatment of chronic lymphocytic leukaemia as an intravenous infusion with a high dose that was administered by a healthcare provider. “The
Let's personalize your content